This inventor holds 2 USPTO granted patents. Top assignee: Gilead Sciences, Inc.. Active years: 2019-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2022
Title: Michael Geier: Innovator in ACC Inhibitor Development
Introduction
Michael Geier is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of Acetyl-CoA carboxylase (ACC) inhibitors. With a total of 2 patents to his name, Geier's work is paving the way for advancements in treating ACC-mediated diseases.
Latest Patents
Geier's latest patents focus on processes for preparing ACC inhibitors and their solid forms. The disclosures provide solid forms, including salts or co-crystals, of Compound I, which exhibit ACC inhibitory activity. These innovations may be useful in treating diseases mediated by ACC. The patents also detail processes for the preparation of Compound I and the intermediates useful for these processes.
Career Highlights
Michael Geier is currently associated with Gilead Sciences, Inc., where he continues to push the boundaries of pharmaceutical research. His work has garnered attention for its potential impact on therapeutic strategies for various diseases.
Collaborations
Geier collaborates with esteemed colleagues, including Mark E Scott and Norihiro Ikemoto, to further enhance the research and development of ACC inhibitors.
Conclusion
Michael Geier's innovative work in the field of ACC inhibitors showcases his commitment to advancing medical science. His contributions are vital for the development of new treatments for ACC-mediated diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile